Evidence map›Paper›PMID 35141003›Full record

ArticleAmerican journal of cancer research2022

Modulation of BRCA1 mediated DNA damage repair by deregulated ER-α signaling in breast cancers.

Arathi Rajan, Geetu R Varghese, Induprabha Yadev, Jaimie Anandan, Neetha R Latha, Dipyaman Patra, Neethu Krishnan, Krithiga Kuppusamy, Arathy V Warrier, Satej Bhushan and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. In vitro study to identify ligand-independent function of estrogen receptor-α in suppressing DNA damage-induced chondrocyte senescence.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Arathi RajanCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Geetu R VargheseCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Induprabha YadevGoverment Medical College Thiruvananthapuram 695011, Kerala, India.
Jaimie AnandanGoverment Medical College Thiruvananthapuram 695011, Kerala, India.
Neetha R LathaCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Dipyaman PatraCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Neethu KrishnanCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Krithiga KuppusamyCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Arathy V WarrierCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Satej BhushanCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Revathy NadhanCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Ram Mohan Ram KumarCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Priya SrinivasCancer Research Program, Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram 695014, Kerala, India.
Rajiv Gandhi Centre for Biotechnology · INKerala Institute of Medical Sciences · INOklahoma State University Oklahoma City · USUniversity of Kerala · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRCA1 mutation carriers have a greater risk of developing cancers in hormone-responsive tissues like breasts and ovaries. However, this tissue-specific incidence of BRCA1 related cancers remains elusive. The majority of the BRCA1 mutated breast cancers exhibit typical histopathological features of high-grade tumors, with basal epithelial phenotype, classified as triple-negative molecular subtype and have a higher percentage of DNA damage and chromosomal abnormality. Though there are many studies relating BRCA1 with ER-α (Estrogen receptor-α), it has not been reported whether E2 (Estrogen) -ER-α signaling can modulate the DNA repair activities of BRCA1. The present study analyzes whether deregulation of ER-α signaling, arising as a result of E2/ER-α deficiency, could impact the BRCA1 dependent DDR (DNA Damage Response) pathways, predominantly those of DNA-DSB (Double Strand break) repair and oxidative damage response. We demonstrate that E2/E2-stimulated ER-α can augment BRCA1 mediated high fidelity repairs like HRR (Homologous Recombination Repair) and BER (Base Excision Repair) in breast cancer cells. Conversely, a condition of ER-α deficiency itself or any interruption in ligand-dependent ER-α transactivation resulted in delayed DNA damage repair, leading to persistent activation of γH2AX and retention of unrepaired DNA lesions, thereby triggering tumor progression. ER-α deficiency not only limited the HRR in cells but also facilitated the DSB repair through error prone pathways like NHEJ (Non Homologous End Joining). ER-α deficiency associated persistence of DNA lesions and reduced expression of DDR proteins were validated in human mammary tumors.

Indexed as

BRCA1DNA damage repairdouble-strand break (DNA-DSB)ER-αhomologous recombination repair (HRR)

Identifiers

PMID35141003
PMCPMC8822286
OpenAlexW4211266951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.